ALK 的研发

过敏研究先锋

了解过敏

ALK 对过敏原及其对人体的影响的认识无与伦比，对过敏症与呼吸道疾病（如哮喘）之间的关系亦有透彻的了解。

Video of understanding_allergy

See all

Post date
12/20/2024
ALK – Financial calendar for the 2025 financial year
Read more
Post date
12/18/2024
Positive results advance peanut tablet to phase II development
Read more
Post date
12/12/2024
ACARIZAX® approved in Europe for treatment of young children
Read more
Post date
11/27/2024
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
Read more
Post date
11/14/2024
Nine-month interim report (Q3) 2024 (unaudited)
Read more
Post date
11/09/2024
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
Read more
Post date
11/07/2024
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
Read more
Post date
08/27/2024
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
Read more
Post date
08/22/2024
Six-month interim report (Q2) 2024
Read more